Effectiveness and cost effectiveness of digital hearing aids in patients with tinnitus and hearing loss: a randomised feasibility trial (THE HUSH Trial).

Feasibility Hearing aids Hearing loss Outcomes Randomised controlled trial Tinnitus

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
03 Nov 2022
Historique:
received: 05 05 2021
accepted: 14 10 2022
entrez: 4 11 2022
pubmed: 5 11 2022
medline: 5 11 2022
Statut: epublish

Résumé

Education and advice is provided for tinnitus management in all UK audiology clinics. Sound therapy, including provision of hearing aids may be offered, but this is often dependent on a clinician's decision rather than UK policy. This inconsistent management reflects a lack of evidence around the effectiveness of hearing aids for tinnitus. This open-label, two-arm multicentre randomised controlled feasibility trial gathered data around recruitment, acceptability and outcome assessments to determine the feasibility of conducting a large randomised controlled trial investigating the effectiveness of hearing aids for tinnitus management. Adults referred to audiology for tinnitus, with an aidable hearing loss were recruited at five UK audiology clinics. They were randomised 1:1 to either education and advice (treatment as usual (TAU), n = 41) or TAU plus hearing aids (n = 42). Outcomes were collected by questionnaires 12 weeks after randomisation. After participation, interviews were conducted with a subset of both participants and clinicians from each trial centre. Eighty three participants from five sites were randomised. Non-aidable hearing loss was the main reason for ineligibility to participate in the trial reported by the sites. Seventy three percent of participants returned the 12-week questionnaires, with return rates by site ranging from 61 to 100%. Fifteen out of 33 participants (45%) reported using hearing aids for the clinician-recommended time, or longer, during the day. The Tinnitus Functional Index (TFI) was the outcome measure most responsive to change. The majority of participants also agreed it was relevant to their tinnitus and hearing loss. Qualitative data demonstrated that the trial was acceptable to participants. Feedback from clinicians revealed a potential lack of equipoise. It also highlighted the differences in referral and treatment pathways between departments and differences in audiometric criteria for fitting hearing aids. Health economic measures were well completed for those returned. No change in health-related quality of life was observed. Costs were higher in the intervention arm, but self-reports of healthcare service use indicated participant confusion in treatment pathways. This feasibility trial is the first step towards obtaining high quality evidence to determine potential clinical effectiveness and cost effectiveness of hearing aids for tinnitus versus usual care. A definitive trial was deemed to be feasible, with some modifications based on feasibility findings and using the TFI as the primary outcome. This trial was funded by the National Institute for Health Research, Research for Patient Benefit Programme (PB-PG-0816-20,014) and registered with ISRCTN (ISRCTN14218416).

Sections du résumé

BACKGROUND BACKGROUND
Education and advice is provided for tinnitus management in all UK audiology clinics. Sound therapy, including provision of hearing aids may be offered, but this is often dependent on a clinician's decision rather than UK policy. This inconsistent management reflects a lack of evidence around the effectiveness of hearing aids for tinnitus. This open-label, two-arm multicentre randomised controlled feasibility trial gathered data around recruitment, acceptability and outcome assessments to determine the feasibility of conducting a large randomised controlled trial investigating the effectiveness of hearing aids for tinnitus management.
METHODS METHODS
Adults referred to audiology for tinnitus, with an aidable hearing loss were recruited at five UK audiology clinics. They were randomised 1:1 to either education and advice (treatment as usual (TAU), n = 41) or TAU plus hearing aids (n = 42). Outcomes were collected by questionnaires 12 weeks after randomisation. After participation, interviews were conducted with a subset of both participants and clinicians from each trial centre.
RESULTS RESULTS
Eighty three participants from five sites were randomised. Non-aidable hearing loss was the main reason for ineligibility to participate in the trial reported by the sites. Seventy three percent of participants returned the 12-week questionnaires, with return rates by site ranging from 61 to 100%. Fifteen out of 33 participants (45%) reported using hearing aids for the clinician-recommended time, or longer, during the day. The Tinnitus Functional Index (TFI) was the outcome measure most responsive to change. The majority of participants also agreed it was relevant to their tinnitus and hearing loss. Qualitative data demonstrated that the trial was acceptable to participants. Feedback from clinicians revealed a potential lack of equipoise. It also highlighted the differences in referral and treatment pathways between departments and differences in audiometric criteria for fitting hearing aids. Health economic measures were well completed for those returned. No change in health-related quality of life was observed. Costs were higher in the intervention arm, but self-reports of healthcare service use indicated participant confusion in treatment pathways.
CONCLUSIONS CONCLUSIONS
This feasibility trial is the first step towards obtaining high quality evidence to determine potential clinical effectiveness and cost effectiveness of hearing aids for tinnitus versus usual care. A definitive trial was deemed to be feasible, with some modifications based on feasibility findings and using the TFI as the primary outcome. This trial was funded by the National Institute for Health Research, Research for Patient Benefit Programme (PB-PG-0816-20,014) and registered with ISRCTN (ISRCTN14218416).

Identifiants

pubmed: 36329548
doi: 10.1186/s40814-022-01188-9
pii: 10.1186/s40814-022-01188-9
pmc: PMC9630825
doi:

Types de publication

Journal Article

Langues

eng

Pagination

235

Subventions

Organisme : Research for Patient Benefit Programme
ID : PB-PG-0816-20014

Informations de copyright

© 2022. The Author(s).

Références

Front Psychol. 2017 Feb 22;8:206
pubmed: 28275357
Ear Hear. 2012 Mar-Apr;33(2):153-76
pubmed: 22156949
J Eval Clin Pract. 2012 Apr;18(2):326-34
pubmed: 21087449
BMC Health Serv Res. 2017 Aug 22;17(1):577
pubmed: 28830503
Neurosci Biobehav Rev. 2011 Apr;35(5):1089-109
pubmed: 21094182
Health Econ. 1997 Jul-Aug;6(4):327-40
pubmed: 9285227
Ear Hear. 2015 May-Jun;36(3):e69-75
pubmed: 25470370
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Ear Hear. 1985 Mar-Apr;6(2):71-5
pubmed: 3996787
J Am Acad Audiol. 2014 Feb;25(2):187-98
pubmed: 24828219
J Laryngol Otol Suppl. 1984;9:17-21
pubmed: 6596358
Pilot Feasibility Stud. 2016 Oct 21;2:64
pubmed: 27965879
Hear Res. 2003 Sep;183(1-2):137-53
pubmed: 13679145
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Pilot Feasibility Stud. 2020 Mar 27;6:41
pubmed: 32231789
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Trends Hear. 2018 Jan-Dec;22:2331216518814384
pubmed: 30488765
Ear Hear. 2015 Jul-Aug;36(4):417-29
pubmed: 25587668
Ear Hear. 1982 May-Jun;3(3):128-34
pubmed: 7095321
Eur J Neurosci. 2006 Jun;23(11):3124-38
pubmed: 16820003
J Speech Lang Hear Res. 2005 Oct;48(5):1204-35
pubmed: 16411806
Cochrane Database Syst Rev. 2017 Sep 25;9:CD012023
pubmed: 28944461
Health Qual Life Outcomes. 2006 Nov 24;4:89
pubmed: 17125512
BMJ. 1996 Apr 20;312(7037):1016-20
pubmed: 8616351
Hear Res. 2018 Feb;358:74-85
pubmed: 29129348
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Neurosci. 2011 Sep 21;31(38):13452-7
pubmed: 21940438
Pharmacoeconomics. 1995 Jun;7(6):490-502
pubmed: 10155335
BMJ Open. 2018 Aug 1;8(7):e021502
pubmed: 30068614
Laryngoscope. 1947 May;57(5):358-66
pubmed: 20241853
Trends Neurosci. 2004 Nov;27(11):676-82
pubmed: 15474168
Hear Res. 2016 May;335:220-235
pubmed: 26415998
Hear Res. 2009 Sep;255(1-2):1-13
pubmed: 19545617
Hear Res. 2016 Jul;337:70-9
pubmed: 27246985
Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1685-93
pubmed: 20577754
J Eval Clin Pract. 2011 Aug;17(4):684-92
pubmed: 21707872
Braz J Otorhinolaryngol. 2010 Jan-Feb;76(1):18-24
pubmed: 20339684
Br J Audiol. 1989 Feb;23(1):53-62
pubmed: 2784987
BMC Health Serv Res. 2018 Feb 13;18(1):110
pubmed: 29433479
Hear Res. 2000 Apr;142(1-2):89-101
pubmed: 10748332
Int J Audiol. 2020 Aug;59(8):567-573
pubmed: 32530329
Hear Res. 2003 Jun;180(1-2):28-38
pubmed: 12782350
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Ear Hear. 2017 Mar/Apr;38(2):149-158
pubmed: 27541331
Cochrane Database Syst Rev. 2018 Dec 27;12:CD013094
pubmed: 30589445
Hear Res. 2009 Jul;253(1-2):15-31
pubmed: 19364527
Med Care. 2002 Feb;40(2):113-28
pubmed: 11802084

Auteurs

Rachel H Haines (RH)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Trish Hepburn (T)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Wei Tan (W)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Clare Jackson (C)

School of Medicine, University of Nottingham, Nottingham, UK.

James Lathe (J)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Jennifer White (J)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Christine Almey (C)

PPI Representative, National Institute for Health and Care Research Nottingham Biomedical Research Centre, Nottingham, UK.

Richard Nicholson (R)

Nottingham University Hospitals NHS Trust, Nottingham, UK.

David Stockdale (D)

British Tinnitus Association, Sheffield, UK.

Paul Leighton (P)

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Marilyn James (M)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Magdalena Sereda (M)

National Institute for Health and Care Research Nottingham Biomedical Research Centre, Nottingham, UK. Magdalena.sereda@nottingham.ac.uk.
Hearing Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK. Magdalena.sereda@nottingham.ac.uk.

Classifications MeSH